doi: 10.1021/jm025529g.
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity
- PMID: 12166927
- DOI: 10.1021/jm025529g
Item in Clipboard
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity
J Med Chem.
.
Abstract
A series of 6alpha-alkyl-substituted analogues of chenodeoxycholic acid (CDCA) were synthesized and evaluated as potential farnesoid X receptor (FXR) ligands. Among them, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) was shown to be a very potent and selective FXR agonist (EC(50) = 99 nM) and to be endowed with anticholeretic activity in an in vivo rat model of cholestasis.
Similar articles
-
Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis.J Pharmacol Exp Ther. 2005 May;313(2):604-12. doi: 10.1124/jpet.104.079665. Epub 2005 Jan 11. J Pharmacol Exp Ther. 2005. PMID: 15644430
-
Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.J Med Chem. 2004 Aug 26;47(18):4559-69. doi: 10.1021/jm049904b. J Med Chem. 2004. PMID: 15317466
-
Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis.J Pharmacol Exp Ther. 2005 Oct;315(1):58-68. doi: 10.1124/jpet.105.085597. Epub 2005 Jun 24. J Pharmacol Exp Ther. 2005. PMID: 15980055
-
[Progress in the ligands and their complex structures of farnesoid X receptor].Yao Xue Xue Bao. 2012 Jun;47(6):704-15. Yao Xue Xue Bao. 2012. PMID: 22919716 Review. Chinese.
-
The farnesoid X receptor: a novel drug target?Expert Opin Investig Drugs. 2004 Sep;13(9):1135-48. doi: 10.1517/13543784.13.9.1135. Expert Opin Investig Drugs. 2004. PMID: 15330745 Review.
Cited by
-
Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy.World J Hepatol. 2015 May 8;7(7):926-41. doi: 10.4254/wjh.v7.i7.926. World J Hepatol. 2015. PMID: 25954476 Free PMC article. Review.
-
Multi-Target Approaches in Metabolic Syndrome.Front Pharmacol. 2021 Mar 12;11:554961. doi: 10.3389/fphar.2020.554961. eCollection 2020. Front Pharmacol. 2021. PMID: 33776749 Free PMC article. Review.
-
Post-Translational Modifications of FXR; Implications for Cholestasis and Obesity-Related Disorders.Front Endocrinol (Lausanne). 2021 Sep 27;12:729828. doi: 10.3389/fendo.2021.729828. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34646233 Free PMC article. Review.
-
Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy.Pharmaceutics. 2023 Jul 16;15(7):1963. doi: 10.3390/pharmaceutics15071963. Pharmaceutics. 2023. PMID: 37514148 Free PMC article. Review.
-
Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation.Nutrients. 2019 May 21;11(5):1132. doi: 10.3390/nu11051132. Nutrients. 2019. PMID: 31117231 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases
